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Compendium of Measures To Control Chlamydia
psittaci  Infection Among Humans (Psittacosis)
and Pet Birds (Avian Chlamydiosis), 1998
Summary
Psittacosis — also known as parrot disease, parrot fever, and ornithosis —
can cause severe pneumonia and other serious health problems among hu-
mans. Approximately 800 cases of psittacosis (infection with Chlamydia psittaci)
were reported to CDC from 1987 through 1996, and most resulted from exposure
to pet birds, usually parrots, macaws, cockatiels, and parakeets. In birds,
C. psittaci infection is referred to as avian chlamydiosis (AC). Infected birds shed
the bacteria through feces and nasal discharges, which can remain infectious for
several months. This compendium provides information about psittacosis and
AC to public health officials, physicians, veterinarians, members of the pet bird
industry, and others concerned about controlling these diseases and protecting
public health. The recommendations in this compendium provide effective,
standardized procedures for controlling AC in birds, a vital step to protecting
human health.
INTRODUCTION
Chlamydia psittaci  is a bacterium that can be transmitted from pet birds to hu-
mans. In humans, the resulting infection is referred to as psittacosis (also known as
parrot disease, parrot fever, and ornithosis). Psittacosis often causes influenza-like
symptoms and can lead to severe pneumonia and nonrespiratory health problems.
With proper treatment, the disease is rarely fatal. From 1987 through 1996, CDC re-
ceived reports of 831 cases of psittacosis (1 ), which is an underestimate of the actual
number of cases because psittacosis is difficult to diagnose.
During the 1980s, approximately 70% of the psittacosis cases with a known source
of infection resulted from human exposure to caged pet birds; of these persons, the
largest group affected (43%) included bird fanciers and owners of pet birds. Pet shop
employees accounted for an additional 10% of cases. Other persons at risk include
pigeon fanciers and persons whose occupation places them at risk for exposure (e.g.,
employees in poultry slaughtering and processing plants, veterinarians, veterinary
technicians, laboratory workers, workers in avian quarantine stations, farmers, and
zoo workers). Because human infection can result from brief, passing exposure to in-
fected birds or their contaminated droppings, persons with no identified leisure-time
or occupational risk can become infected.
In this report, C. psittaci  infection in birds is referred to as avian chlamydiosis (AC).
The bacterium C. psittaci  has been isolated from approximately 100 bird species and
is most commonly identified in psittacine birds such as parrots, macaws, cockatiels,
and parakeets. Among caged, nonpsittacine birds, infection with C. psittaci  occurs
most frequently in pigeons, doves, and mynah birds. The incidence of infection in
canaries and finches is believed to be lower than in other psittacine birds. 
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The recommendations in this compendium provide effective, standardized proce-
dures for controlling AC in the pet bird population, an essential step in efforts to
control psittacosis among humans. This compendium is intended to guide public
health officials, physicians, veterinarians, persons in the pet bird industry, and others
concerned with the control of C. psittaci  infection and the protection of public health.
PART I. INFECTION AMONG HUMANS (PSITTACOSIS)
Transmission
Because several diseases affecting humans can be caused by other species of
Chlamydia, the disease resulting from the infection of humans with C. psittaci  fre-
quently is referred to as psittacosis rather than chlamydia. Most C. psittaci  infections
in humans result from exposure to pet psittacine birds. Infection with C. psittaci  usu-
ally occurs when a person inhales the organism, which has been aerosolized from
respiratory secretions or dried feces of infected birds. Other means of exposure in-
clude bird bites, mouth-to-beak contact, and the handling of infected birds’ plumage
and tissues. Even brief exposures can lead to symptomatic infection; therefore, some
patients with psittacosis may not recall or report having any contact with birds.
Mammals occasionally transmit C. psittaci  to humans. Certain strains of C. psittaci
infect sheep, goats, and cattle, causing chronic infection of the reproductive tract, pla-
cental insufficiency, and abortion in these animals. These strains of C. psittaci  are
transmitted to persons when they are exposed to the birth fluids and placentas of
infected animals. Another strain of C. psittaci, feline keratoconjunctivitis agent, typi-
cally causes rhinitis and conjunctivitis in cats. Transmission of this strain from cats to
humans appears to occur rarely.
Human-to-human transmission has been suggested but not proven. Standard
infection-control precautions are sufficient for patients with psittacosis, and specific
isolation procedures (e.g., a private room, negative pressure air flow, and masks) are
not indicated.
Clinical Signs and Symptoms
For persons infected with C. psittaci, the onset of illness follows an incubation
period of 5–14 days. The severity of this disease ranges from inapparent illness to
systemic illness with severe pneumonia. Before antimicrobial agents were available,
15%–20% of persons with C. psittaci  infection were reported to have died. However,
<1% of properly treated patients now die as a result of the infection.
Persons with symptomatic infection typically have abrupt onset of fever, chills,
headache, malaise, and myalgia. They usually develop a nonproductive cough that
can be accompanied by breathing difficulty and chest tightness. A pulse-temperature
dissociation (fever without elevated pulse), enlarged spleen, and rash are sometimes
observed and suggest a diagnosis of psittacosis for patients with community-acquired
pneumonia. Auscultatory findings may underestimate the extent of pulmonary
involvement. Radiographic findings include lobar or interstitial infiltrates. The differ-
ential diagnosis of psittacosis-related pneumonia includes infection with Coxiella
burnetii, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella  species, and
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respiratory viruses such as influenza. C. psittaci  can affect organ systems other than
the respiratory tract and result in endocarditis, myocarditis, hepatitis, arthritis, kerato-
conjunctivitis, and encephalitis. Severe illness with respiratory failure, thrombo-
cytopenia, hepatitis, and fetal death has been reported among pregnant women. 
Diagnosis
A patient is considered to have a confirmed  case of psittacosis if clinical illness is
compatible with psittacosis and the case is laboratory confirmed by one of three
methods: a) C. psittaci  is cultured from respiratory secretions; b) antibody against
C. psittaci  is increased by fourfold or greater (to a reciprocal titer of ≥32 between
paired acute- and convalescent-phase serum specimens collected at least 2 weeks
apart) as demonstrated by complement fixation (CF) or microimmunofluorescence
(MIF); or c) immunoglobulin M antibody against C. psittaci  is detected by MIF (to a
reciprocal titer of ≥16). A patient is considered to have a probable  case of psittacosis
if clinical illness is compatible with psittacosis and a) the case is epidemiologically
linked to a confirmed case of psittacosis or b) a single antibody titer ≥32, demon-
strated by CF or MIF, is present in at least one serum specimen obtained after onset of
symptoms. CDC and the Council of State and Territorial Epidemiologists established
these case definitions for epidemiologic purposes (2 ). These definitions should not be
used as the sole criteria for establishing clinical diagnoses.
Until recently, the diagnosis almost always was established by using serologic
methods in which paired sera were tested for Chlamydia  antibodies by CF test. How-
ever, because Chlamydia  CF antibody is not species-specific, high CF titers also may
result from Chlamydia pneumoniae  and Chlamydia trachomatis  infection. Acute-
phase serum specimens should be obtained as soon as possible after the onset of
symptoms, and convalescent-phase serum specimens should be obtained ≥2 weeks
after the onset of symptoms. Because treatment with tetracycline can delay or dimin-
ish the antibody response, a third serum sample might help confirm the diagnosis. All
sera should be tested simultaneously at the same laboratory. If the patient’s
epidemiologic and clinical history indicate a possible diagnosis of psittacosis, MIF
assays can be used to distinguish C. psittaci  infection from infection with other
chlamydial species. Information about laboratory testing often is available at state
laboratories. The infectious agent also can be isolated from the patient’s sputum, pleu-
ral fluid, or clotted blood during acute illness and before treatment with antimicrobial
agents; however, culture of C. psittaci  is performed by few laboratories because of
technical difficulty and safety concerns.
Treatment
Tetracyclines are the drugs of choice for treating patients with psittacosis. Most
persons respond to oral therapy (100 mg of doxycycline administered twice a day or
500 mg of tetracycline hydrochloride administered four times a day). For initial treat-
ment of severely ill patients, doxycycline hyclate may be administered intravenously
at a dosage of 4.4 mg/kg (2 mg/lb) body weight per day divided into two infusions per
day (up to 100 mg per dose). In past years, tetracycline hydrochloride has been admin-
istered to patients intravenously (10–15 mg/kg body weight per day divided into four
doses per day), but a preparation for injection is no longer available in the United
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States. Remission of symptoms usually is evident within 48–72 hours. However,
relapse can occur, and treatment must continue for at least 10–14 days after fever
abates. Although its in vivo efficacy has not been determined, erythromycin probably
is the best alternative agent for persons for whom tetracycline is contraindicated (e.g.,
children aged <9 years and pregnant women).
PART II. INFECTION AMONG BIRDS (AVIAN CHLAMYDIOSIS)
Transmission
Shedding of the infectious agent among birds with latent chlamydiosis may be ac-
tivated by several stress factors, including shipping, crowding, chilling, and breeding.
Birds can appear healthy but be carriers of C. psittaci  and can shed the organism
intermittently. When shedding occurs, the organism is excreted in the feces and nasal
discharges of infected birds. The organism is resistant to drying and can remain infec-
tious for several months.
Clinical Signs
For caged birds, the time between exposure to C. psittaci  and the onset of illness
ranges from 3 days to several weeks. However, latent infections are common among
birds, and active disease may appear years after exposure. C. psittaci  infection in
birds can be asymptomatic or can result in an acute, subacute, or chronic clinical dis-
ease. Whether the bird exhibits clinical signs of illness or dies depends on the species
of bird, virulence of the strain, infectious dose, stress factors, age, and extent of treat-
ment or prophylaxis.
Birds with clinical signs of AC typically have manifestations (e.g., lethargy, ano-
rexia, and ruffled feathers) consistent with those of other systemic illnesses. Other
signs associated with AC include serous or mucopurulent ocular or nasal discharge,
diarrhea, and excretion of green to yellow-green urates. Anorectic birds may produce
sparse, dark green droppings. Birds can die soon after onset of illness or, as the dis-
ease progresses, can become emaciated and dehydrated before death.
Diagnosis
Several diagnostic methods are available for identifying AC in birds (Appendix A).
A confirmed  case of AC is defined as infection with C. psittaci  on the basis of at least
one of the following laboratory results: a) isolation of C. psittaci  from a clinical speci-
men, b) identification of chlamydial antigen by immunofluorescence (fluorescent
antibody [FA]) of the bird’s tissues, c) a greater than fourfold change in serologic titer
in two specimens from the bird obtained at least 2 weeks apart and assayed simulta-
neously at the same laboratory, or d) identification of C. psittaci  within macrophages
in smears stained with Gimenez or Macchiavellos stain or sections of the bird’s
tissues.
A probable  case of AC is defined as C. psittaci  infection in a bird that has clinical
illness compatible with AC and at least one of the following laboratory results: a) a
single high serologic titer in one or more specimens obtained after the onset of signs
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or b) the presence of C. psittaci  antigen (identified by enzyme-linked immunosorbent
assay [ELISA] or FA) in feces, a cloacal swab, or respiratory or ocular exudates.
A suspected  case of AC is defined as a) clinical illness compatible with AC that is
epidemiologically linked to another case in a human or bird but that is not laboratory
confirmed, b) an asymptomatic infection in a bird with a single high serologic titer or
detection of chlamydial antigen, c) illness in a bird that has positive results for infec-
tion on the basis of a nonstandardized test or a new investigational test, or d) a clinical
illness compatible with chlamydiosis that is responsive to appropriate therapy.
Treatment
Veterinarians can choose from three types of methods for treating birds with AC —
medicated feed (chlortetracycline), oral or parenteral treatment (doxycycline
or oxytetracycline), and experimental treatment (fluoroquinolones, late-generation
macrolides, pharmacist-compounded injectable doxycycline, and doxycycline-
medicated feed) (Appendix B). Although these protocols are usually successful,
knowledge about AC treatment is evolving, and no treatment protocol guarantees
safe treatment or complete elimination of infection by the etiologic agent C. psittaci  in
all bird species. Therefore, treatment should be supervised by a licensed veterinarian.
PART III. RECOMMENDATIONS AND REQUIREMENTS
Recommendations for Controlling Infection Among
Humans and Birds
To prevent the transmission of C. psittaci  to persons and other birds, the following
control measures are recommended for physicians, veterinarians and their staffs, and
members of the pet bird industry:
• Take measures to protect persons at high risk from becoming infected. All per-
sons in contact with infected birds should be informed about the nature of the
disease. If a person who has been exposed develops respiratory illness, the phy-
sician should initiate early and specific treatment for psittacosis. Persons at risk
should be instructed to wear protective clothing, gloves, a paper surgical cap,
and a respirator with an N95 rating or a higher-efficiency respirator when clean-
ing cages or handling infected birds. Surgical masks may not be effective in
preventing transmission of C. psittaci. When necropsies are performed on poten-
tially infected birds, additional precautions should be taken, including a) wetting
the carcass with detergent and water to prevent aerosolization of infectious par-
ticles and b) working under an examining hood that has an exhaust fan.
• Maintain accurate records of all bird-related transactions to aid in identifying
sources of infected birds and potentially exposed persons. Records should in-
clude the date of purchase, species of birds purchased, source of birds, and any
identified illnesses or deaths among birds. In addition, when birds are sold by a
store, the seller should record the name, address, and telephone number of the
customer; the date of purchase; the species of birds purchased; and the band
numbers if applicable.
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• Do not purchase or sell birds that have signs of AC (e.g., ocular or nasal dis-
charge, diarrhea, or low body weight).
• Quarantine newly acquired birds for 30–45 days, and test or prophylactically treat
them before adding them to a group. 
• Consider birds that have been to shows, exhibitions, fairs, and other events as
newly acquired birds, and quarantine them upon return to the facility.
• Test birds for AC before they are to be boarded or sold on consignment, and
house them in a room separate from other birds.
• Practice preventive husbandry. Position cages to prevent the transfer of fecal
matter, feathers, food, and other materials from one cage to another. Do not stack
cages, and be sure to use solid-sided cages or barriers if cages are adjoining. The
bottom of the cage should be made of wire mesh, and litter that will not produce
dust (e.g., newspapers) should be placed underneath the mesh. Clean all cages
and food and water bowls daily. Soiled bowls should be emptied, cleaned with
soap and water, rinsed, placed in a disinfectant solution, and rinsed again before
reuse. Between occupancies by different birds, cages should be thoroughly
scrubbed with soap and water, disinfected, and rinsed in clean, running water.
Exhaust ventilation should be sufficient to prevent accumulation of aerosols.
• Prevent the spread of infection. If AC is confirmed, probable, or suspected, birds
requiring treatment should be held in isolation. Rooms and cages where infected
birds were housed should be cleaned immediately and disinfected thoroughly to
eliminate chlamydial organisms from the environment. When the cage is being
cleaned, transfer the bird to a clean cage. Thoroughly scrub the soiled cage with
a detergent to remove all fecal debris, rinse the cage, disinfect it (allowing at least
5 minutes of contact with the disinfectant), and rerinse the cage to remove the
disinfectant. Discard all items that cannot be adequately disinfected (e.g.,
wooden perches, nest material, and litter). While birds are being treated, mini-
mize the circulation of feathers and dust by taking precautions such as wet-
mopping the floor frequently with disinfectants and preventing air currents and
drafts within the area. Reduce contamination from dust by spraying the floor
with a disinfectant or water before sweeping it. Do not use a vacuum cleaner,
because vacuuming can cause aerosolization of infectious particles. Frequently
remove waste material from the cage (after moistening the material), and burn or
double-bag the waste for disposal. When possible, care for healthy birds before
handling isolated birds.
• Use disinfection measures. Because C. psittaci  has a high lipid content, it is sus-
ceptible to most disinfectants and detergents. In the clinic or laboratory, a 1:1,000
dilution of quaternary ammonium compounds (e.g., Roccal® or Zephiran®) is ef-
fective, as is 70% isopropyl alcohol, 1% Lysol®, 1:100 dilution of household
bleach (i.e., 2.5 tablespoons per gallon [10 mL/L]), or chlorophenols. (C. psittaci is
susceptible to heat but is resistant to acid and alkali.) Many disinfectants are res-
piratory irritants and should be used in a well-ventilated area. Avoid mixing
disinfectants with any other product.
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Recommendations for Treating and Caring for Infected Birds
All birds with confirmed or probable AC should be isolated and treated, preferably
under the supervision of a veterinarian (Appendix B). Birds with suspected AC or birds
previously exposed to AC should be isolated and retested or treated. Because treated
birds can be reinfected with C. psittaci  after treatment, such birds should not be ex-
posed to untreated birds or other potential sources of infection. To prevent reinfection
from environmental sources, aviaries should be thoroughly cleaned and sanitized. No
vaccine against chlamydiosis in birds is available.
The following general recommendations should be followed by bird owners and
dealers when treating and caring for birds with confirmed, probable, or suspected
cases of AC:
• Protect birds from undue stress (e.g., chilling or shipping), poor husbandry, or
malnutrition. These problems reduce the effectiveness of treatment and promote
the development of secondary infections with other bacteria or yeast.
• Observe the birds daily, and weigh them every 3–7 days. If the birds are not main-
taining weight, have them reevaluated by a veterinarian.
• Do not administer antimicrobial agents to birds through drinking water, and
avoid the use of high dietary concentrations of calcium or other divalent cations.
• Isolate birds that are to be treated in clean, uncrowded cages, segregated by sex.
• Clean up all spilled food promptly; wash food and water containers daily.
• Provide fresh water and appropriate vitamins daily. 
• Continue medication for the full treatment period to avoid relapses. Birds may
appear clinically improved and have reduced shedding after 1 week.
Responsibilities of Veterinarians and Physicians
Veterinarians should be aware that AC is not a rare disease among pet birds and
should consider a diagnosis of AC for any lethargic bird that has nonspecific signs of
illness, especially if the bird was purchased recently. If AC is suspected, the veterinar-
ian should submit appropriate laboratory specimens to a veterinary diagnostic
laboratory to confirm the diagnosis. Both laboratories and attending veterinarians
should follow local and state regulations or guidelines regarding case reporting.
Veterinarians should work closely with authorities who conduct investigations in their
jurisdictions. When appropriate, veterinarians should inform clients that infected birds
should be isolated and treated. In addition, they should educate clients about the pub-
lic health hazard posed by AC and the appropriate precautions that should be taken to
avoid the risk for transmission. Persons exposed to the birds should seek medical
attention if they develop influenza-like symptoms or other respiratory illness.
Most states require physicians to report cases of psittacosis among humans to the
appropriate health authorities. Timely diagnosis and reporting may help identify the
source of infection and control the spread of disease. Because single-serum titers are
both insensitive and nonspecific for diagnosis of psittacosis, confirmation with paired
acute- and convalescent-phase sera is recommended. Birds that are suspected
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sources of human infection should be referred to veterinarians for evaluation and
treatment. Local and state authorities may conduct epidemiologic investigations and
institute additional disease-control measures (see Local and State Epidemiologic
Investigations).
Quarantine of Birds
The appropriate animal and public health authorities may issue a quarantine for all
affected and susceptible birds on a premises where C. psittaci  infection has been
identified. The purpose of imposing a quarantine is not to discourage disease report-
ing but to prevent further disease transmission (3 ). Because of the severe economic
impact of quarantines, reasonable economic options should be made available to the
owners and operators of pet stores. For example, with the approval of state or local
authorities, the owner of quarantined birds may choose to a) treat the birds in a sepa-
rate quarantine area to prevent exposure to the public and other birds or b) euthanize
the infected birds. After completion of the treatment or removal of the birds, a quaran-
tine can be lifted when the infected premises are thoroughly cleaned and disinfected.
The area can then be restocked with birds.
Bird Importation Regulations
The Veterinary Services of the Animal and Plant Health Inspection Service, U.S.
Department of Agriculture (USDA), regulates the importation of pet birds to ensure
that exotic poultry diseases are not introduced into the United States. These regula-
tions are set forth in the Code of Federal Regulations, Title 9, Chapter 1 (3 ). Because of
the possibility of smuggled pet birds, these import measures do not guarantee that AC
cannot enter the United States. In general, current USDA regulations regarding the
importation of birds include the following requirements:
• Before shipping the birds, the importer must obtain an import permit from the
USDA and a health certificate issued and/or endorsed by a veterinarian of the
national government of the exporting country.
• A USDA veterinary inspection must be conducted at the first port of entry in the
United States and a quarantine be imposed for a minimum of 30 days at a USDA-
approved facility, to determine whether the birds are free of evidence of
communicable diseases of poultry. In addition, the birds must be tested to ensure
they are free of exotic Newcastle disease and pathogenic avian influenza.
• During the 30-day U.S. quarantine, psittacine birds must receive a balanced,
medicated feed ration containing ≥1% chlortetracycline (CTC) with ≤0.7% calcium
for the entire quarantine period as a precautionary measure against AC. The
USDA recommends that importers continue CTC prophylactic treatment of psit-
tacine birds for an additional 15 days (i.e., for 45 continuous days).
Local and State Epidemiologic Investigations
Public health or animal health authorities at the local or state level may need to
conduct epidemiologic investigations to help control the transmission of C. psittaci  to
humans and birds. An epidemiologic investigation should be initiated if a) a bird with
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confirmed or probable AC was procured from a pet store, breeder, or dealer within
60 days of the onset of signs of illness, b) a person has confirmed or probable psitta-
cosis, or c) several suspect avian cases have been identified from the same source.
Other situations may be investigated at the discretion of the appropriate local or state
public health departments or animal health authorities. 
Investigations involving recently purchased birds should include a visit to the site
where the infected bird is located and identification of the location where the bird was
originally procured (e.g., pet shop, dealer, breeder, or quarantine station). During such
investigations, authorities should consider documenting the number and types of
birds involved, the health status of potentially affected persons and birds, locations of
facilities where birds were housed, relevant ventilation-related factors, the treatment
protocol, and the source of medicated feed, if such treatment is initiated. To help iden-
tify multistate outbreaks of C. psittaci  infection, local and state authorities should
report suspected outbreaks to the Respiratory Diseases Branch, Division of Bacterial
and Mycotic Diseases, National Center for Infectious Diseases, CDC, telephone
(404) 639-2215.
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Appendix A
METHODS FOR DIAGNOSING AVIAN CHLAMYDIOSIS
Histopathologic Findings
In birds that have avian chlamydiosis (AC), cloudy air sacs and an enlarged liver
and spleen usually are observed, but no specific gross lesion is pathognomonic. The
chromatic or immunologic staining of tissue-impression smears can be used to iden-
tify organisms.
Culture Technique
Isolation of the etiologic agent, Chlamydia psittaci, from the bird’s spleen, liver, air
sacs, pericardium, heart, or intestines is the optimal means for verifying the diagnosis.
Chlamydia  organisms are obligate intracellular bacteria that must be isolated in tis-
sue culture, mice, or chick embryos. Specialized laboratory facilities and training are
necessary both for reliable identification of chlamydial isolates and for adequate
protection of microbiologists. Consequently, few laboratories perform chlamydial
cultures.
In live birds, depending on which clinical signs they exhibit, combined cloacal and
choanal-swab specimens should be collected, refrigerated, and sent to the laboratory
packed in ice, but not frozen. The proper handling of samples is critical for maintaining
the viability of organisms for culture, and a special transport medium is required. Vet-
erinarians should contact their specific diagnostic laboratory for procedures required
for submission of specimens for isolation.
Live birds being screened for C. psittaci  might not shed the microorganism daily.
Therefore, to reduce laboratory costs, serial specimens should be collected for
3–5 consecutive days and pooled before being cultured. Tissue samples from the
bird’s liver and spleen are the preferred necropsy specimens for isolation of C. psittaci.
When legal actions may result from chlamydiosis cases, use of culture is recom-
mended to avoid limitations associated with other tests.
Tests for Antibody
A major problem with serologic testing is the interpretation of results. A positive
serologic test result is evidence that the bird was infected by C. psittaci  in the past, but
it does not prove that the bird currently has active disease. False-negative results may
occur for birds that have acute infection when they are sampled before seroconver-
sion. Treatment with an antimicrobial agent may diminish the antibody response.
A single testing method may not be adequate because of the diversity of reactions
with immunoglobulins from the various avian species. Therefore, the use of a combi-
nation of antibody- and antigen-detection methods for the diagnosis of chlamydiosis
is recommended, particularly when only one bird is tested. When specimens are
obtained from a single bird, serologic testing is most useful when a) signs of disease
and the history of the flock or aviary are considered and b) serologic results are
compared with the white blood cell counts and liver-enzyme activities. A greater than
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fourfold increase in titer of paired samples or a combination of a titer and antigen
identification is needed to confirm a diagnosis of chlamydiosis. Some of the advan-
tages and disadvantages of two serologic tests for antibodies are described in the
following paragraphs.
Direct Complement-Fixation (CF) Test
Direct CF is more sensitive to antibody activity than are agglutination methods. No
commercial antigen is available. False-negative results are possible in specimens
from small psittacine birds (e.g., budgerigars, young African grey parrots, and love-
birds). High titers may persist after treatment and complicate interpretation of
subsequent tests. Modified direct CF is more sensitive than direct CF.
Elementary-Body Agglutination (EBA)
EBA is commercially available and can detect early infection. Titers ≥10 in budgeri-
gars, cockatiels, and lovebirds and titers ≥20 in larger birds indicate current infection.
However, positive titers may persist after treatment is completed, and EBA is per-
formed only by one U.S. laboratory.
Tests for Antigen
Immunofluorescent-Staining Tests
Monoclonal or polyclonal antibodies, fluorescein-staining techniques, and fluores-
cent microscopy are used to identify infectious agents in impression smears from
dead birds. When used with cloacal or fecal smears, the sensitivity and specificity of
the test are questioned by some authorities. The test is most useful if the bird is shed-
ding antigen. Its advantages are that it gives rapid results and does not require live,
viable organisms. Laboratory experience is important for accurate interpretation of
immunofluorescent stains.
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA tests (i.e., IDEIA®) now used to identify C. psittaci  were originally developed
for identification of the lipopolysaccharide antigen on Chlamydia trachomatis, which
is a human pathogen. The exact sensitivity and specificity of these tests for identifying
C. psittaci  are not known. Although the test is most useful in clinically ill birds, the
sensitivity may be low in asymptomatic birds because of intermittent shedding. More-
over, some tests may be falsely positive because of cross-reaction with other bacteria.
The test results must be evaluated in conjunction with other clinical findings. If a bird
has a positive ELISA result but is clinically healthy, the veterinarian should attempt to
verify that the bird is shedding antigen through isolation of the organism. When a
clinically ill bird has a negative ELISA result, a diagnosis of AC cannot be excluded
without further testing (e.g., isolation, serologic testing, or fluorescent antibody).
Additional Tests
Additional diagnostic techniques are in use or under development, including
polymerase chain reaction tests. Readers are encouraged to research peer-reviewed
reports on such tests before use.
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Laboratories that Test for C. psittaci 
The National Association of State Public Health Veterinarians (NASPHV) can pro-
vide a list of laboratories that offer testing for C. psittaci. Address requests to NASPHV,
RSA Tower, Suite 1310, P.O. Box 303017, Montgomery, AL 36130-3017.
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Appendix B
TREATMENT OPTIONS FOR PET BIRDS
WITH AVIAN CHLAMYDIOSIS
The following methods are established as effective treatments for avian chlamy-
diosis (AC). All birds with AC should be treated for 45 days, except as noted below:
Medicated Feed
Medicated feed should be the only food provided to the birds during the entire
treatment. Birds’ acceptance of medicated feed is variable. Thus, food consumption
should be monitored. Acceptance may be enhanced by first adapting the birds to a
similar, nonmedicated diet. Treatment begins when the birds accept the medicated
feed as the sole food in their diet. The following options are available:
• Medicated mash diets (i.e., ≥1% chlortetracycline [CTC] with ≤0.7% calcium) pre-
pared with corn can be used.*
• White millet seed impregnated with 0.5 mg CTC/g of seed (Keet Life®) should be
used for budgerigar parakeets and finches only. It should be used for 30 days.
Hartz Mountain (Secaucus, New Jersey) is the only manufacturer.
• Pellets and extruded products containing 1% CTC can be used. They are available
and appropriate for use with most pet birds. Select a pellet size appropriate for
the size of bird being treated.
• A special diet might be necessary for lories and lorikeets, which feed on nectar
and fruit in the wild.
The National Association of State Public Health Veterinarians (NASPHV) can pro-
vide a list of companies that sell medicated feed. Address requests to NASPHV, RSA
Tower, Suite 1310, P.O. Box 303017, Montgomery, AL 36130-3017.
Oral or Parenteral Treatments
Three treatments available include oral doxycycline, injectable doxycycline, and in-
jectable oxytetracycline.
Oral Doxycycline
Doxycycline is the drug of choice for oral treatment; either the monohydrate or
calcium-syrup formulations can be used. Based on nonpeer-reviewed studies, dosage
recommendations are as follows: 40–50 mg/kg body weight by mouth once a day for
cockatiels, Senegal parrots, and blue-fronted and orange-winged Amazon parrots;
and 25 mg/kg body weight by mouth once a day for African grey parrots, Goffin’s
cockatoos, blue and gold macaws, and green-winged macaws. Precise dosages
*The recommended recipe is 2 pounds of rice, 2 pounds of hen scratch feed, and 3 pints of
water, cooked for 15 minutes at full pressure in a pressure cooker. Add 10 mg chlortetra-
cycline/g of feed after the cooked feed cools. Note that birds may find this diet unpalatable
and may not accept it.
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cannot be extrapolated for untested species; however, 25–30 mg/kg body weight ad-
ministered by mouth once a day is the recommended starting dosage for cockatoos
and macaws, and 25–50 mg/kg by mouth once a day is recommended for other psit-
tacine species. If the bird regurgitates the drug, another treatment method should be
used.
Injectable Doxycycline
Intramuscular (IM) injection into the pectoral muscle is often the easiest method of
treatment, but not all injectable-doxycycline formulations are suitable for IM injection.
All available formulations can cause irritation at the injection site. The Vibrovenos
formulation (Pfizer Laboratories, London, Ontario, Canada) is available in Canada and
Europe and is effective if administered at doses of 75–100 mg/kg body weight IM every
5–7 days for the first 4 weeks and subsequently every 5 days for the duration of
treatment. Anecdotal reports indicate that pharmacist-compounded, injectable-
doxycycline products have been used successfully in the United States. However, data
are insufficient to determine precise dosage schedules. The injectable-hyclate formu-
lation labeled for intravenous use in humans in the United States is not suitable for IM
use in birds because severe tissue reactions will occur at the site of injection.
Injectable Oxytetracycline
Limited information exists for the use of an injectable, long-acting oxytetracycline
product (LA-200; Pfizer Laboratories, Exton, Pennsylvania). Current dosage recom-
mendations are as follows: subcutaneous injection of 75 mg/kg body weight every 3
days in Goffin’s cockatoos, blue-fronted and orange-winged Amazon parrots, and blue
and gold macaws. This dosage may be suitable for but has not been tested on other
species. This product causes irritation at the site of injection and is best used to initiate
treatment in ill birds or those that are reluctant to eat. After stabilization with
oxytetracycline treatment, the birds should be switched to another form of treatment
to reduce the muscle irritation that is caused by repeated oxytetracycline injection.
Experimental Methods
Treatment protocols using fluoroquinolones, late-generation macrolides,
pharmacist-compounded injectable doxycycline, and doxycycline-medicated feed are
under investigation. Information about these treatment protocols may be available in
the scientific literature or from avian veterinary specialists.
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